NYSE - Nasdaq Real Time Price USD

Boston Scientific Corporation (BSX)

Compare
101.94
+0.30
+(0.30%)
At close: January 24 at 4:00:02 PM EST
101.75
-0.19
(-0.18%)
After hours: January 24 at 7:57:33 PM EST
Loading Chart for BSX
DELL
  • Previous Close 101.64
  • Open 101.01
  • Bid 101.75 x 800
  • Ask 101.90 x 800
  • Day's Range 100.91 - 102.15
  • 52 Week Range 60.78 - 102.15
  • Volume 4,324,566
  • Avg. Volume 5,492,246
  • Market Cap (intraday) 150.242B
  • Beta (5Y Monthly) 0.80
  • PE Ratio (TTM) 84.25
  • EPS (TTM) 1.21
  • Earnings Date Feb 5, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 102.15

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

www.bostonscientific.com

48,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BSX

View More

Performance Overview: BSX

Trailing total returns as of 1/24/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

BSX
13.67%
S&P 500
3.29%

1-Year Return

BSX
68.16%
S&P 500
25.42%

3-Year Return

BSX
137.24%
S&P 500
38.73%

5-Year Return

BSX
133.97%
S&P 500
83.47%

Compare To: BSX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BSX

View More

Valuation Measures

As of 1/24/2025
  • Market Cap

    150.24B

  • Enterprise Value

    159.00B

  • Trailing P/E

    84.25

  • Forward P/E

    36.36

  • PEG Ratio (5yr expected)

    1.85

  • Price/Sales (ttm)

    9.50

  • Price/Book (mrq)

    7.26

  • Enterprise Value/Revenue

    9.99

  • Enterprise Value/EBITDA

    42.67

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.26%

  • Return on Assets (ttm)

    4.90%

  • Return on Equity (ttm)

    8.92%

  • Revenue (ttm)

    15.91B

  • Net Income Avi to Common (ttm)

    1.79B

  • Diluted EPS (ttm)

    1.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.5B

  • Total Debt/Equity (mrq)

    53.72%

  • Levered Free Cash Flow (ttm)

    1.8B

Research Analysis: BSX

View More

People Also Watch